Recent Advances in Clinical Trials

Recent Advances in Clinical Trials

Open Access
ISSN: 2771-9057
Case Report

Persistent Shoulder Pain Revealing a Metastatic Proximal Humeral Lesion from Occult Lung Adenocarcinoma: An Interdisciplinary Diagnostic Challenge

Authors: Zayd Alhiasat, Sandy Mahd.

DOI: 10.33425/2771-9057.1096


Abstract

Shoulder pain is a common complaint encountered in primary care and is most frequently attributed to benign musculoskeletal conditions. However, persistent symptoms that fail to respond to conventional treatment may occasionally represent the first manifestation of a serious underlying disease. Bone metastases are a common complication of advanced lung cancer, yet they rarely present as the initial clinical feature in the absence of respiratory symptoms. We report the case of a 58-yearold man who presented with progressive atraumatic shoulder pain initially diagnosed as rotator cuff tendinopathy in a family medicine setting. Despite conservative management, his symptoms worsened and became associated with nocturnal pain, fatigue, and unintentional weight loss. Further investigation revealed anemia, elevated inflammatory markers, and an osteolytic lesion of the proximal humerus. Advanced imaging identified a previously undiagnosed pulmonary mass, and histopathological examination confirmed metastatic lung adenocarcinoma. The patient underwent prophylactic orthopaedic fixation of the humerus followed by systemic oncological treatment. This case highlights the importance of recognizing redflag symptoms in patients with persistent musculoskeletal pain and emphasizes the value of interdisciplinary collaboration between family medicine, internal medicine, radiology, pathology, orthopaedic oncology, pulmonology, and medical oncology.

View / Download PDF
Citation: Zayd Alhiasat, Sandy Mahd. Persistent Shoulder Pain Revealing a Metastatic Proximal Humeral Lesion from Occult Lung Adenocarcinoma: An Interdisciplinary Diagnostic Challenge. Recent Adv Clin Trials. 2026; 6(6). DOI: 10.33425/2771-9057.1096
Editor-in-Chief
Mike Robinson
Mike Robinson
Medical Department | Global Cannabinoid Research Center

View full editorial board →
Journal Metrics
Impact Factor 2.9*
Acceptance Rate 80%
Time to first decision 5-8 Days
Submission to acceptance 12-15 Days